US FDA Commissioner Scott Gottlieb touted the use of combined-phase studies, or "seamless trials," by oncology sponsors, indicating that the method could become more widely adopted beyond the field of cancer drug development.
Speaking at the Regulatory Affairs Professionals Society Regulatory Convergence Conference Sept. 11 in Oxon Hill, Md., Gottlieb pointed to seamless...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?